chlormezanone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
603 80-77-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clormezanone
  • chlormezanone
  • chlormethazanone
  • chlormethazone
  • dichloromezanone
  • phenarol
  • dl-Chlormezanone
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
  • Molecular weight: 273.73
  • Formula: C11H12ClNO3S
  • CLOGP: 1.57
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 54.45
  • ALOGS: -2.23
  • ROTB: 1

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
May 20, 1960 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Temperature regulation disorder 526.58 110.14 101 2375 4126 50598522
Food allergy 460.62 110.14 101 2375 8036 50594612
Coeliac disease 448.55 110.14 100 2376 8585 50594063
Immunodeficiency 400.32 110.14 101 2375 14727 50587921
Bursitis 360.20 110.14 101 2375 22034 50580614
Rash erythematous 319.08 110.14 102 2374 34750 50567898
Fluid retention 277.94 110.14 101 2375 50548 50552100
Upper respiratory tract infection 248.59 110.14 100 2376 65798 50536850
Hyperhidrosis 228.72 110.14 103 2373 89323 50513325
Asthma 219.26 110.14 100 2376 89237 50513411
Hepatic enzyme increased 181.23 110.14 101 2375 137279 50465369
Erythema 180.62 110.14 103 2373 146311 50456337
Constipation 150.62 110.14 100 2376 185608 50417040
Hypersensitivity 144.20 110.14 103 2373 215058 50387590
Back pain 142.13 110.14 103 2373 219927 50382721
Rheumatoid arthritis 138.06 110.14 98 2378 202452 50400196
Drug hypersensitivity 127.86 110.14 102 2374 250908 50351740

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Temperature regulation disorder 548.64 165.20 100 2288 4111 64492233
Food allergy 486.47 165.20 100 2288 7751 64488593
Coeliac disease 486.28 165.20 99 2289 7313 64489031
Immunodeficiency 414.80 165.20 100 2288 16024 64480320
Bursitis 386.29 165.20 100 2288 21385 64474959
Rash erythematous 313.69 165.20 102 2286 48531 64447813
Fluid retention 285.60 165.20 100 2288 59506 64436838
Upper respiratory tract infection 262.44 165.20 99 2289 72686 64423658
Asthma 236.64 165.20 99 2289 95126 64401218
Hyperhidrosis 213.93 165.20 100 2288 124820 64371524
Hepatic enzyme increased 210.16 165.20 100 2288 129843 64366501
Erythema 181.20 165.20 102 2286 186968 64309376
Rheumatoid arthritis 179.46 165.20 97 2291 164197 64332147
Hypersensitivity 179.23 165.20 103 2285 196349 64299995

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03BB02 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB52 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB72 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35476 neuroleptics
CHEBI has role CHEBI:51371 muscle relaxants
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018260 VUID
N0000146590 NUI
D00268 KEGG_DRUG
2373 RXNORM
4018260 VANDF
C0008223 UMLSCUI
CHEBI:3619 CHEBI
CHEMBL1200714 ChEMBL_ID
DB01178 DRUGBANK_ID
D002720 MESH_DESCRIPTOR_UI
2717 PUBCHEM_CID
7323 IUPHAR_LIGAND_ID
782 INN_ID
GP568V9G19 UNII
4413 MMSL
d00909 MMSL
001447 NDDF
387400008 SNOMEDCT_US
71634000 SNOMEDCT_US

Pharmaceutical products:

None